ATE411038T1 - S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung - Google Patents

S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung

Info

Publication number
ATE411038T1
ATE411038T1 AT04723142T AT04723142T ATE411038T1 AT E411038 T1 ATE411038 T1 AT E411038T1 AT 04723142 T AT04723142 T AT 04723142T AT 04723142 T AT04723142 T AT 04723142T AT E411038 T1 ATE411038 T1 AT E411038T1
Authority
AT
Austria
Prior art keywords
protein
activator
cancer treatment
neutrophil cells
reduce neutropenia
Prior art date
Application number
AT04723142T
Other languages
English (en)
Inventor
Philippe Tessier
Karen Vandal
Pascal Rouleau
Carle Ryckman
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE411038T1 publication Critical patent/ATE411038T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04723142T 2003-03-28 2004-03-25 S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung ATE411038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45802203P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
ATE411038T1 true ATE411038T1 (de) 2008-10-15

Family

ID=33098257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723142T ATE411038T1 (de) 2003-03-28 2004-03-25 S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung

Country Status (6)

Country Link
US (1) US7632802B2 (de)
EP (1) EP1608397B1 (de)
AT (1) ATE411038T1 (de)
CA (1) CA2520515C (de)
DE (1) DE602004017148D1 (de)
WO (1) WO2004084928A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427758T1 (de) * 2002-07-05 2009-04-15 Univ Laval Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
WO2006005186A1 (en) * 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia
HUE035043T2 (en) * 2006-10-30 2018-05-02 Genomix Co Ltd A pharmaceutical composition for promoting functional regeneration of damaged tissue
CN102076351A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 损伤组织的功能性再生促进药物
RU2519714C2 (ru) * 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
CN102083962B (zh) 2008-04-30 2013-03-27 吉诺米克斯股份有限公司 生物体内功能性细胞的高效采集方法
US8173598B2 (en) 2008-08-29 2012-05-08 The Board Of Trustees Of The University Of Illinois Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway
EP2494977B1 (de) 2009-10-28 2018-06-13 Genomix Co., Ltd. Geweberegenerationsförderer mit rekrutierung mesenchymaler knochenmarkstammzellen und/oder pluripotenter stammzellen in blut
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
PL2913059T3 (pl) 2012-10-25 2018-09-28 Genomix Co., Ltd. Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1
MX361259B (es) 2012-10-25 2018-11-30 Univ Osaka Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
WO2016134463A1 (en) * 2015-02-25 2016-09-01 UNIVERSITé LAVAL S1009a peptide for treating leukemias
AU2018213671B2 (en) 2017-01-27 2024-06-06 Osaka University Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
EP3718561A4 (de) 2017-12-01 2021-07-21 Stemrim Inc. Therapeutikum für entzündliche darmerkrankung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
FR2587707B1 (fr) 1985-09-23 1988-01-08 Compiegne Universite Technolog Glycopeptide et toute composition le contenant, leur procede de preparation et leurs applications anticoagulantes
EP0263072B1 (de) 1986-10-03 1994-03-23 Ciba-Geigy Ag Lymphokin-ähnliche Peptide
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
WO1992004376A1 (en) 1990-09-05 1992-03-19 The Heart Research Institute Limited Novel chemotactic factor
ATE206056T1 (de) 1992-06-08 2001-10-15 Takeda Chemical Industries Ltd Therapeutisches agens für neutropenie
WO1997034013A1 (en) 1996-03-11 1997-09-18 Human Genome Sciences, Inc. Chemotactic cytokine ii
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
DE19811047C1 (de) 1998-03-13 1999-04-15 Fraunhofer Ges Forschung Metallhaltige Ribonukleotidpolypeptide
US6117989A (en) 1998-03-26 2000-09-12 Incyte Pharmaceuticals, Inc. Human calcium-binding proteins
CA2346217A1 (en) 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
EP1066834A3 (de) 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
ATE427758T1 (de) 2002-07-05 2009-04-15 Univ Laval Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
WO2006005186A1 (en) 2004-07-13 2006-01-19 UNIVERSITé LAVAL S100 protein inhibitors for treating leukemia

Also Published As

Publication number Publication date
CA2520515C (en) 2012-08-28
EP1608397A1 (de) 2005-12-28
DE602004017148D1 (de) 2008-11-27
WO2004084928A1 (en) 2004-10-07
US20060281674A1 (en) 2006-12-14
CA2520515A1 (en) 2004-10-07
EP1608397B1 (de) 2008-10-15
US7632802B2 (en) 2009-12-15

Similar Documents

Publication Publication Date Title
ATE411038T1 (de) S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
Muzaki et al. Intestinal CD103+ CD11b− dendritic cells restrain colitis via IFN-γ-induced anti-inflammatory response in epithelial cells
Alvarez et al. Regulatory T cell phenotype and anti-osteoclastogenic function in experimental periodontitis
van Leuven et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
ATE381336T1 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
DE60224291D1 (de) System zur antikörperexpression und- synthese
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
Yang et al. Molecular mechanisms of osteogenesis and antibacterial activity of Cu-bearing Ti alloy in a bone defect model with infection in vivo
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
Sonouchi et al. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2.
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE523591T1 (de) Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
Katakura et al. Paralogs of common carp granulocyte colony-stimulating factor (G-CSF) have different functions regarding development, trafficking and activation of neutrophils
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
EA200600936A1 (ru) Способы регуляции фактора некроза опухоли альфа
ES2365463T3 (es) Fotoféresis extracorpórea en combinación con tratamiento anti-tnf.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties